FDAsafety guidance72% confidence
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Merck.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · Renal Cell Carcinoma
- Sub-indication
- General
Related signal: Merck and Eisai's LITESPARK-012 Trial Fails to Meet Primary Endpoints in RCC